Health
Multi-million pound cancer immunotherapy platform launched across the UK
Image: Scientists working in the laboratory
A new multi-million pound research program involving scientists from London's Institute of Cancer Research aims to find out why at least half of all patients do not respond to treatment. immunotherapy or suffer from debilitating side effects.
Funded by £9m from the Medical Research Council and Office for Life Sciences, and £12.9m matched by industry partners, the program will see thousands of patients treated with immunotherapy from across the UK. join.
Drugs that help the immune system fight cancer, collectively known as immunotherapy, are front-line treatments for several types of cancer, including: melanoma skin cancer. Long-term studies have shown that advanced disease can be completely eradicated in some patients.
However, at least half of cancer patients do not benefit, and many have recurrence or experience serious side effects. Among them melanomain the most successful immunotherapies, only 50% respond.
Assessing barriers to immunotherapy
A new UK-wide program called MANIFEST (Multiple Analysis of Immunotherapy Signatures for Proving Success and Toxicity) has been established to assess barriers to immunotherapy success.
These include the lack of testable and usable biological indicators; biomarkersuggests to doctors whether someone would benefit from a particular drug. Identifying these biomarkers may not only help select patients who are most likely to benefit, but also reveal the path to new treatments such as vaccines and cell therapies. MANIFEST aims to develop tests that can verify which biomarkers are present in patients before starting immunotherapy and monitor them during treatment.
The initial test will include 3,000 patients who have already completed treatment, followed by a further 3,000 patients starting treatment across the UK. chest, bladder, kidney and skin cancermore cancer types will be included as the program expands.
Data will be collected from these patients over a four-year period using procedures such as blood tests, stool samples, and tissue biopsies. The research team plans to analyze various aspects of cancerous tumors, including their genetic makeup, their relationship with immune cells, and what chemical signals cancerous tumors emit.
We also plan to generate a profile of immune cells in each patient's bloodstream and analyze their gut microbiome.
“We have a unique opportunity to accelerate further discovery.”
Professor Samra Turajlicproject leader, Francis Crick Institute Clinical Group Leader, Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trustgroup leader at the London Institute of Cancer Research, said:
“While great advances have been made in cancer treatment using immunotherapy over the past decade, many patients remain undertreated due to treatment failures and side effects.
“The UK has a unique opportunity to meet this challenge with the NHS. We are very excited to be working with such a large number of clinicians, patients and industry partners, each with their own unique experience and expertise. We are delighted that research of this scale will not only bring us one step closer to better tests in the clinic, but will also ultimately drive further discoveries in cancer immunology and new treatments across the UK. We want to accelerate the delivery of personalized medicine for diseases that affect millions of people every year.”
Professor Manuel Sarto-TellesProfessor of Integrative Pathology, London Cancer Institute, And the lead Integrated Integrative Pathology Unit He, from the Institute for Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust, said:
“Immunotherapies have revolutionized the treatment of some patients, but we still have a long way to go. We need something more complex. biomarker To overcome complex diseases like cancer. MANIFEST aims to identify new and better biomarkers to predict response to immunotherapy. ”
MANIFEST was launched as part of the Department of Science, Innovation and Technology's initiative to provide funding to support cancer diagnosis and treatment.
Science and Technology Secretary Peter Kyle said:
“Cancer is a disease that has brought pain, misery and heartbreak to every family in this country, including my own. But by working with the NHS, researchers and businesses, the Government can harness science and innovation. “We can bring the detection and treatment of this terrible disease firmly into the 21st century and keep more families together for longer.” They have great ideas that will not only promote our health, but also our economy, creating a virtuous cycle of further investment in both health and research, and ultimately driving economic growth. “Improve the standard of living.” ”
Alex's story – “Immunotherapy saved my life”
Alex Green, 42, from Surrey, was first diagnosed with melanoma in 2012 and was treated with surgery. Unfortunately, three years later, the disease managed to spread to the lymph nodes and Alex was referred. The Royal Marsden. Alex underwent several surgeries to remove the tumor, followed by postoperative radiation therapy and then immunotherapy.
Alex said, “It's done.” radiation therapy My scans were clear, but less than two years later the cancer returned. was offered immunotherapy And it totally saved my life. Without that, I would have passed away in 2019, leaving behind my wife and two children, ages 4 and 7 at the time. It was a life-changing treatment for me and I am now 8 years into complete remission and able to lead a normal, active life. Although the results of this treatment were amazing, it also came with some difficult challenges. I suffered some pretty serious side effects and had to be hospitalized for two weeks. I fully understand that it is important to research and understand the side effects of immunotherapy in order to make the treatment as effective and as gentle as possible. ”
Collaboration with industry
The consortium's industry partners bring new technology and immunotherapy expertise to support the implementation of these discoveries in the clinic. UK-based company IMU Biosciences has joined the MANIFEST consortium to analyze thousands of blood samples from patients undergoing immunotherapy. They use a detailed profiling platform to identify which immune cells are present in the bloodstream and use machine learning to predict whether individual differences in immune cells influence treatment response. .
Adam Lane, President and CSO of IMU Biosciences, said:
“The IMU team is thrilled to be able to provide our cutting-edge AI-driven immune profiling platform to this ground-breaking UK consortium. The ultimate goal is to improve clinical outcomes in cancer patients. “
The project involves 16 academic institutions, including the Francis Crick Institute; Cancer Research Institute, London. University of Edinburgh; Manchester Institute for Cancer Research UK; National Pathology Imaging Collaborative; Genomics England; Hull York Medical School, University of York. University of Cambridge; Queen Mary University of London. University of St. Andrews. Queen's University Belfast; UCL; University of Manchester; University of Glasgow; Cancer Research UK and Scotland; Cancer Research UK National Biomarker Center; and six NHS Foundation Trusts: Royal Marsden NHS Foundation Trust. NHS Lothian; Cambridge University Hospitals NHS Foundation Trust. Barts Health NHS Trust. Leeds Teaching Hospitals NHS Trust and The Christie NHS Foundation Trust.
MANIFEST collaborates with 11 industry partners. Oxford Nanopore Technologies; Roche Pharma and Diagnostics Division, and Roche imCORE Network. From molecules to medicine. Guardant Health; Natera; Microbiology. 10x Genomics; Akoya Bioscience, Univ8 Genomics.
The consortium will also collaborate with AstraZeneca. Bristol-Myers Squibb; Immunocore; MSD; Amazon Web Services; Indica Labs. Manifesto is also working with 12 networks across the UK to recruit patients into clinical trials, and three patient organizations (BRC RM/ ICR Patient and Public Contributor Working Group, Melanoma Focus, and Action Kidney Cancer).
Sources 2/ https://www.icr.ac.uk/news-archive/multi-million-pound-uk-wide-platform-into-cancer-immunotherapy-launches The mention sources can contact us to remove/changing this article |
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]